Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -91.08% | 2,289.94% | 1,819.67% | -99.06% |
| Total Other Revenue | -- | 92.28% | -41.51% | -- | -- |
| Total Revenue | -- | -9.09% | 2,348.43% | 1,819.67% | -99.06% |
| Cost of Revenue | -- | -100.00% | -98.99% | -99.73% | -99.50% |
| Gross Profit | -- | 101.46% | 2,939.42% | 274.89% | -98.68% |
| SG&A Expenses | -76.03% | 0.50% | -84.94% | -34.69% | 68.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 3,891.67% | -256.48% | -- | -- |
| Total Operating Expenses | -75.59% | -25.57% | -85.22% | -50.28% | 39.57% |
| Operating Income | 75.58% | 25.65% | 103.08% | 55.48% | -48.90% |
| Income Before Tax | 67.75% | 124.55% | 96.03% | 38.05% | -54.32% |
| Income Tax Expenses | -- | -100.00% | 140.00% | -235.74% | -- |
| Earnings from Continuing Operations | 67.75% | 118.41% | 96.01% | 45.03% | -54.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.20% | -68.33% | -203.36% | 402.90% | 27.21% |
| Net Income | 70.29% | 159.82% | 94.38% | 55.26% | -55.41% |
| EBIT | 75.58% | 25.65% | 103.08% | 55.48% | -48.90% |
| EBITDA | 75.82% | 26.60% | 103.42% | 55.95% | -49.34% |
| EPS Basic | 80.66% | 130.31% | 98.17% | 86.93% | 47.21% |
| Normalized Basic EPS | 82.89% | -7.33% | 97.83% | 86.86% | 46.98% |
| EPS Diluted | 80.66% | 129.59% | 97.56% | 86.84% | 47.21% |
| Normalized Diluted EPS | 82.89% | -7.33% | 97.83% | 86.86% | 46.98% |
| Average Basic Shares Outstanding | 53.74% | 97.77% | 205.90% | 242.17% | 194.36% |
| Average Diluted Shares Outstanding | 53.74% | 97.77% | 205.90% | 242.17% | 194.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |